Carryover acceptable

Acceptance criteria the active ingredient in the hnal rinse is not detected, equal to, or less than the maximum allowable carryover limit determined. 

Usually the most difficult aspect of cleaning validation is in determining how to evaluate the efficacy of the cleaning method. Equipment should be sufficiently clean so that the incidental carryover in the first batch after cleaning presents an acceptable risk to excipient quality and performance. Once this determination has been made, it is possible to calculate the maximum amount of residue carried over into the excipient batch. Then a calculation can be made as to how much residue can be left on the equipment surface, assuming the residue is uniform throughout the equipment. 

Determining what is an acceptable amount of residue remaining on the equipment is at the very heart of cleaning verification and validation. The determination of acceptable carryover limits for pharmaceutical equipment and facilities is actually addressing the question of What is clean To those who feel that equipment and facilities should always be cleaned to the level of analytical detectability, I will only say that approach is certainly always acceptable, and in some cases, a very reasonable approach. In most cases, however, cleaning to the lowest level of analytical detectability has a couple of major disadvantages. The first problem with this approach is that current analytical capability is so incredibly sensitive that the previously manufactured product(s) can almost al-... 

Acceptance. It is acceptable if carryover blank has analyte peaks that are <20.0 % of the lowest peak area of the acceptable LLOQ and carryover blank has internal standard peaks that are <5.00 % of the mean peak area of internal standard in the run. 

The second method uses the 10 ppm limit historically used to calculate commercial manufacturing limits. This method allows the maximum carryover of product A to be calculated using lot sizes and shared equipment surface area, regardless of the potency of the prior lot. The formula below shows the method used to develop the 10 ppm acceptance limits ... 

After the limits are calculated for all products that are to be processed and all equipment used, the limits are compared. The smallest limit calculated for a product using all of the calculations becomes the acceptance limit for the cleaning verification for that product. If product B, the lot to be manufactured next, is unknown at the time of manufacture of Product A, the worse case should be assumed in the calculation. For example, if the smallest lot that has ever been manufactured in the facility is 5000 dosage units, or alternatively 1 kg, those values should be used in the equation to generate a maximum allowable carryover of product A. To reiterate some of the initial points, the rationale for which equation is utilized should be documented, and the limits that are established should be practical, achievable, and verifiable based on the most deleterious residue. 

The requirements for combustion control of incinerators used for disposal of toxic materials are far more severe than for combustors burning more conventional fuels. Whereas a combustion efficiency of 99% may be quite acceptable for a fossil-fuel-fired energy conversion system, the carryover of 1 % of the feed from an incinerator results in an unacceptable release to the environment. 

In the early days of biotechnology product development, the focus was on quality issues [4] or process-related impurities.The concerns at that time were for carryover of other cellular proteins and DNA and for contamination with endotoxins, chemicals, and viruses. Of course, these concerns still exist, but methods for purification and assays for evaluation of clearance have alleviated the need for the safety assessment scientist to focus on contaminants instead they are now asked to focus on the pharmacological activity of the molecules. An ICH guidance (Q6B Specifications Test Procedures and Acceptance Criteria for Biotechnological/Biological Products) addresses the specific issues related to the manufacturing process [6], Other product-related issues such as impurities do need to be considered by the safety assessment scientist, for... 

The TE column is equilibrated with a minimum of two solvent combinations. The first solvent is strong, to wash the TE column free of impurities it may have accumulated from a previous sample (remember, this column is used over and over, so this step is critical so there is no sample carryover). This solvent is probably pure methanol or acetonitrile if using a reversed-phase filled TE column. The second solvent is not strong it is used to bring the TE column to equilibrium to accept the sample components of in-... 

Problems such as swab recoverability or interference with adhesive materials are commonly encountered during the swab selection process. It is imperative that the swab selected be compatible with the diluent, the detergents, and the chemical (active/degradant) and it cannot cause interference with the method used for residue analysis, typically FIPLC and/or TOC. A swab recovery study is required for determining the acceptability of a swab. This is performed by spiking the swab with known quantities of the various chemicals under evaluation for potential carryover. The swabs need to be analyzed by the validated method to be used in the cleaning validation studies. An acceptable level of recovery should be no less than 70% and a correction factor needs to be included in final residue calculations. 

Inorganic impurities are normally detected and quantified using pharmacopoeia or other appropriate procedures. Carryover of catalysts to a new drug substance should be evaluated during development. The need for inclusion or exclusion of inorganic impurities in a new drug substance specification should be discussed. Acceptance criteria should be based on pharmacopoeial standards or known safety data. 

Several samples are simultaneously handled in the analytical path the number should be as high as possible at any one time in order to optimise the sampling frequency for a given mean sample residence time and an acceptable degree of carryover [7], However, this number cannot be increased at will due to tailing effects, which are a consequence of sample broadening, and manifest themselves mainly at the sample edges (Fig. 5.5). 

---